Indication

For treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.

Medicine details

Medicine name:
tepotinib (Tepmetko)
SMC ID:
SMC2457
Pharmaceutical company
Merck Serono Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
13 June 2022
SMC meeting date:
03 May 2022
Patient group submission deadline:
28 February 2022